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ABSTRACT 
 
Hypoxia-sensitive gene expression in the gastrocnemius muscle following chronic hind 
limb ischemia 
 
Andrew Tilton 
 
Chronic ischemia, caused by the formation atherosclerotic plaque occlusions in 
major conduit arteries, is the leading cause of morbidity and mortality in western 
societies. Vascular remodeling can help compensate for the adverse effects of 
atherosclerotic plaque formation. Vascular remodeling relies heavily on vascular 
endothelial growth factor (VEGF), a critical protein that contributes to all forms of 
vascular formation and remodeling including angiogenesis
1
, arteriogenesis
2
 and 
vasculogenesis
3
. VEGF itself is up-regulated by the transcription factor, hypoxia 
inducible factor 1 alpha (HIF-1α), which becomes activated in low oxygen environments.  
Through the use of animal chronic hindlimb ischemia models, these genes can be 
evaluated as potential therapeutic targets for chronic ischemia. A modified hindlimb 
ischemia surgery that we evaluated significantly increases VEGF expression, but does not 
cause an up-regulation of HIF-1α. This research lays the foundation for further 
investigation into the animal chronic hindlimb ischemia model by providing the 
necessary protocols and molecular biology techniques. The next step in this line of 
research should focus on protein quantification in the gastrocnemius muscle and 
verification of the gene expression profile described in this report.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
: the growth of new blood vessels from pre-existing vessels 
2
: the increase in diameter of pre-existing vessels in order to accommodate for greater      
flow through them 
3
: the growth of new blood vessels via de novo generation of endothelial cells 
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Chapter 1. Introduction 
OVERVIEW 
Peripheral artery disease (PAD) is a condition of the vascular system in which 
large arteries become occluded and prevent proper blood flow to the extremities [1]. The 
disease is commonly caused by atherosclerotic plaque formation along the vascular walls, 
which results in downstream ischemia [1]. Ischemia is characterized by insufficient blood 
flow to tissues and leads to poor nutrient supply and hypoxia [2]. In healthy tissue, 
vasodilation is used in response to the onset of hypoxia as a way to restore proper oxygen 
levels in the tissue. In patients with PAD, vasoactivity is impaired and vessels cannot 
vasodilate properly in response to signals from the tissue. 
The disease is becoming more and more common as the rate of obesity continues 
to increase in the U.S. There are several contributing factors that lead to the formation of 
the plaque along the artery wall (Figure 1), including diabetes mellitus, smoking, 
hypertension, and hypercholesteremia. The development of PAD in patients is an 
accurate indicator of overall decreased cardiovascular health and suggests that blood 
vessel occlusions are likely to develop elsewhere in the body as well. The general 
symptoms are typically noticed in the legs, but blood flow will likely be reduced in the 
heart and brain as well. Therefore, PAD is a useful indicator of many other related 
conditions, including coronary heart disease, which can cause a myocardial infarction.  
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PAD presents itself differently in every patient and about 20% of people with the 
disease are asymptomatic [1]. The most common symptom of the disease is intermittent 
claudication (irregular pain) in the extremities, caused by ischemia, and usually occurs 
during locomotion. When PAD progresses to the point where the patient experiences 
intermittent claudication, they have a significantly increased risk of mortality from 
cardiovascular disease. In extreme cases of PAD, limb ischemia is so severe that 
gangrene develops as a result of insufficient blood flow. It is not uncommon for these 
symptoms to eventually result in amputation. Unfortunately, PAD is at times difficult to 
detect, especially in asymptomatic patients.  
Currently, the most commonly used diagnostic tool for assessing the status of a 
patient with PAD is a simple and noninvasive procedure, called the Ankle Brachial 
Pressure Index (ABPI) test [4]. The test is administered by using a Doppler ultrasound 
Figure 1. Diagram of atherosclerotic plaque occluded artery of 
PAD patient compared to normal artery. The figure depicts the 
narrow lumen, characteristic of occluded artery [3]. 
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instrument to detect blood flow to the lower extremities and a blood pressure cuff at the 
arm. Using these devices together the blood pressure in the posterior tibial artery is 
compared to the blood pressure in the brachial artery. The results from the test are 
reported as a ratio between the lower leg and upper arm. Atherosclerotic plaques in 
peripheral arteries will cause decreased blood flow in the lower extremities. A healthy 
ABPI is in the range of 0.9-1.3 indicating that the blood pressure between the legs and 
arms is roughly the same. ABPI ratios between 0.4 and 0.9 are indicative of moderate 
PAD and values below 0.4 suggest severe PAD.  
The atherosclerotic plaques responsible for the occlusions of PAD patients are 
composed of three distinct layers [5]. The initial layer, found at the center of the plaque is 
comprised of monocytes and other cellular debris. The plaques first begin to form where 
turbulent flow occurs in the blood vessel, which generally occurs near a bifurcation. The 
turbulent flow patterns induce the activation of endothelial cells, which line the blood 
vessels, causing them to present adhesion molecules on their surface [6]. Among the 
adhesion molecules presented is the protein, vascular cell adhesion protein 1 (VCAM-1), 
which is recognized and bound by monocytes. Upon activation, monocytes begin to 
differentiate into macrophages, which phagocytose oxidized low density lipoproteins 
(LDL). This is an important step in the body’s natural defense against atherosclerotic 
plaque formation because the lipoproteins build upon the first layer and enlarge the 
occlusion [7]. However, the situation is exaggerated as the macrophages then presents 
oxidized LDLs antigens on their surface and activate T helper cells [8]. As T helper cells 
become activated they excrete inflammatory cytokines such as interferon-γ. The second 
layer of the atherosclerotic plaque is primarily a crystalized coating of cholesterol and 
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low-density lipoproteins that have accumulated at the site [8]. The final layer is a 
calcification layer and is only present in older, more advanced, plaque. The calcification 
makes the artery stiff and inflexible.  
 
CURRENT TREATMENTS FOR PAD 
The most important and effective treatment for patients with PAD is to monitor 
the contributing causes of the disease and eliminate them whenever possible. For 
example, maintaining a healthy diet and regular exercise routine will help lower blood 
pressure and cholesterol. It is also important to monitor blood sugars and keep them 
within a normal range. Current non-invasive treatments for PAD include cholesterol-
lowering medications, hypertension medications, and anti-clotting agents to name a few 
[1, 9].  
 Non-invasive treatments are much more desirable methods of curing patients 
compared to invasive surgical methods because they are far less risky [1, 9]. With 
cholesterol lowering medications, the goal is to reduce the patient’s risk of heart attack 
and stroke. This method effectively targets and treats the underlying cause of PAD. It is 
important in people with PAD to reduce their LDL levels to a healthy range (<100 
mg/dL), in order to control fat and cholesterol transport throughout the body. When too 
much LDL circulates in the blood, it can slowly build up along the inner walls of arteries 
and aid in the formation of plaque.  
 Anti-coagulates are also widely prescribed to PAD patients as a way to help 
reduce the risk of blood clots forming [1, 9]. Patients with PAD are at greater risk of clots 
forming at the occlusion site because there is a reduced blood flow through the area. A 
blood clot that forms in the artery can completely block the already narrowed blood 
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vessel. This could lead to tissue death if not treated promptly. Further, if a clot that forms 
in the leg manages to break away it can cause a stroke if it makes its way to the brain, or 
cause a heart attack if it travels through a vital cardiac artery. However, while this 
treatment is somewhat effective, it only addresses a symptom of the disease and does 
nothing to treat the underlying cause.  
 However, while these drugs are somewhat effective, many of them merely treat 
the symptoms rather than the cause of the disease. Another option that is highly effective 
and minimally invasive is an angioplasty [1, 9]. An angioplasty (figure 2) is often used 
when the PAD is causing intermittent claudication, or muscle pain, in the patient. An 
angioplasty involves threading a catheter through the blood vessel to the affected region 
of the artery. A balloon is located at the tip of the catheter, which can be inflated to 
reopen the artery. At the same time, the occlusion is flattened into the artery wall and the 
artery wall stretches, which increases blood flow. An optional addition to the procedure is 
the use of a stent, or mesh frame that can be inserted into the site to help keep the artery 
open even after the procedure is over. 
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Another surgical treatment implemented by doctors to treat PAD is bypass 
surgery [1, 9]. While this procedure is equally effective, or even better for some patients, 
it is far more complicated than the angioplasty procedure. This operation requires the 
surgeon to create a graft bypass by using a vessel from somewhere else in the patient’s 
body. However, recent advances are allowing for the use of synthetic vessels to be used. 
The bypass procedure allows for blood to flow around the occluded region. One 
limitation to these procedures is that they are only effective if only one artery is 
obstructed. For more systemic conditions, these techniques will be largely ineffective. As 
with any invasive surgery, there are risks, including infection or death. 
While these treatments are somewhat effective and have helped many patients 
suffering from PAD, they are insufficient for many people. The bypass procedure is 
insufficient because without addressing the cause, another occlusion may quickly form 
Figure 2. Diagram of angioplasty procedure depicting the process of 
threading the catheter balloon into the occluded area where it can be 
inflated to flatted the plaque and stretch the vessel wall thus increasing 
blood flow through the vessel. Not shown is the process of stent insertion 
[10].  
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and vessels for additional bypass procedures may not be available. Angioplasty does not 
always work either because the occluded vessels are too small, or have become calcified, 
making them inaccessible by the catheter. For many patients, surgery is contraindicated 
due to current health status and the risk of complications during the procedure. Therefore, 
research to provide additional approaches is needed. 
  
VASCULAR REMODELING AND REACTIVITY 
When healthy, and functioning properly, tissues control blood flow via 
autoregulation [11, 12]. This is the ability to adjust blood flow in response to various 
signals such as vessel pressure and metabolic levels. Regular changes in blood vessel 
diameter to regulate blood flow throughout the body are referred to as vasoactivity. 
Vasoactivity is achieved through vasoconstriction and vasodilation (figure 3b) of the 
vascular smooth muscle and serves two major physiological purposes [11, 12]. First, it 
regulates systemic blood pressure and second, it is used to redirect blood flow through 
different regions of the body. The ability of a vessel to constrict and dilate is imperative 
to maintaining homeostasis in the tissue by meeting the demand of oxygen and nutrients 
in the downstream tissues.  In healthy tissue, vasodilation is used in response to the onset 
of hypoxia to restore proper in response to the onset of hypoxia to restore proper oxygen 
levels in the tissue. This effect can last for several hours. In patients with PAD, the 
vasoactivity is impaired and vessels cannot vasodilate in response to signals from the 
tissue.  
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The vasculature can adapt to an arterial occlusion such as that caused by an 
atherosclerotic plaque by network remodeling, which is primarily done in three distinct 
ways. The first is vasculogenesis [15], which is the de novo generation of capillaries 
through the merging of endothelial cells. Vasculogenesis primarily occurs during 
embryonic development; however it also occurs in response to severe hypoxia. The 
second form of remodeling is angiogenesis [16], where new capillaries grow from pre-
existing capillaries in response to tissue hypoxia. The third, and final, process used to 
remodel the vascular network is arteriogenesis [16, 17], in which pre-existing vessels 
increase in diameter to restore endothelial shear stresses following an increase in blood 
flow through collateral flow paths. These three mechanisms can effectively compensate 
for the effects of an atherosclerotic plaque, and are therefore targets for novel therapeutic 
Figure 3 A) Blood vessel anatomy depicting the several layers that comprise the vessel and 
enabling it to function [13]. B) Effects of vasodilation and constriction of blood vessel 
diameter [14]. 
A. 
B. 
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modalities. When these mechanisms are implemented together, collaterals enlarge from 
pre-existing vessels and are capable of delivering sufficient blood flow to the tissue. In 
both vasculogenesis and angiogenesis, increasing the number of capillaries present allows 
for improved diffusion in the ischemic region.  
 Molecular analysis of gene expression will be useful in better understanding 
signaling pathways involved in the vascular remodeling response to arterial occlusion. 
Angiogenesis can be induced by several factors, including hypoxia, which will be the 
main focus of this paper [16, 18]. When a cell senses hypoxia, it activates the 
transcription factor Hypoxia inducible factor 1 (HIF1) [18]. HIF1 is responsible for 
increasing the transcription of hypoxia-sensitive genes encoding essential proteins 
involved in the remodeling process, including several growth factors. One of the most 
well studied genes up regulated by HIF1 is Vascular endothelial growth factor (VEGF) 
[19]. VEGF stimulates both vasculogenesis and angiogenesis in response to tissue 
hypoxia by inducing the division of endothelial cells (figure 4). It is typically highly 
functional during embryonic development, following an injury, and following intense 
muscle activity in an attempt to create new blood vessels. Once functional, it is capable 
of binding the VEGF receptor expressed on endothelial cells. The receptor is a tyrosine 
kinase (RTK), which begins an angiogenesis pathway. VEGF is essential for collaterals 
and collateral growth, allowing a tissue to have several different pathways for blood to be 
delivered. However, while VEGF is necessary for collateral proliferation, it alone is not 
sufficient to overcome the hypoxia [20]. 
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HIF1 alpha (HIF1α) is a well-established transcription factor regulated by the 
availability of oxygen to the cell [18, 19]. The protein is a heterodimer that is capable of 
entering the nucleus of the cell, where it binds to specific regions of the DNA and 
activates a variety of hypoxia response genes. HIF1α is, itself, regulated by the 
transcription factor NF-κB. Post translation, HIF1α is maintained at appropriate levels via 
Ard1 [22]. HIF1 is a constitutively active gene, in which transcripts are constantly being 
produced and translated. However, under normoxic conditions, Ard1 acetylates a lysine 
Figure 4. VEGF pathway within endothelial cell showing the downstream 
effects, which eventually result in proliferation and vascular permeability 
[21]. 
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residue within the oxygen-dependent degradation domain, thus marking it for degradation 
by ubiquitin.  HIF1α is also involved in a positive feedback loop in which the functional 
transcription factor binds to a promoter region and activates itself. Under low levels of 
hypoxia, HIF1α can be active and functional without increasing its own transcription 
level [23].  
While vascular remodeling may help the body adapt to vascular occlusions by 
creating a natural bypass, previous research in the MATR lab shows that it may also be a 
detriment by impairing vascular reactivity [24]. Homeostasis heavily relies on 
vasoactivity in order to sufficiently meet the oxygen and nutrient demand in tissues. The 
process of vessel outward remodeling may impair vasodilation, most likely by 
interrupting the vasodilation signal transmission of endothelial cells.  
There are two likely explanations for the impaired vasodilation observed after 
outward network remodeling takes place. The first possible explanation is that the 
process of synthesizing new extracellular matrix material impairs the ability of smooth 
muscle cells to contract and relax, and disables the vessels ability to undergo 
vasoactivity. Another possible explanation is that inflammation, which occurs during 
arteriogenesis and is a common symptom of PAD, causes endothelial dysfunction and 
significantly diminishes blood flow. Normally, endothelial cells initiate vasodilation by 
releasing nitric oxide caused by shear stress to the vessel. However, during inflammation, 
superoxide is produced from cytokine activation of NADPH oxidase, which inactivates 
nitric oxide thus inhibiting the endothelial cells ability to induce vasodilation [25].  
These explanations for impaired vasodilation observed in mouse models may also 
explain the impaired vasoactivity seen in patients with PAD where inflammatory 
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responses include atherosclerosis and arteriogenesis. Further evidence supporting this 
hypothesis can be drawn from PAD patients with non-occluded vessels that still present 
with impaired vasoactivity [26]. 
Using the mouse as a model for the simulation requires a significant portion of the 
femoral-saphenous artery-vein pair must be removed, in order to generate sufficient 
levels of hypoxia in the hindlimb and induce angiogenesis because of their extensive 
collateral vascular networks. In this experiment, a modified resection surgery will remove 
a section of the femoral artery. As a result, the hindlimb should become dependent on 
reperfusion from deep collaterals in order to survive.  
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Chapter 2. Project Design, Goals, and Hypothesis 
In this study, arterial resection in the mouse hindlimb will be used to model the 
chronic ischemia aspect of PAD. Using the mouse as a model for the simulation requires 
a significant portion of the femoral-saphenous artery-vein pair to be removed in order to 
generate sufficient levels of hypoxia in the hindlimb and induce angiogenesis because of 
their extensive collateral vascular networks. In this experiment, a modified resection 
surgery will remove a section of the femoral artery. As a result, the hindlimb should 
become dependent on reperfusion from deep collaterals in order to survive.  
Since hypoxia is a primary stimulator of angiogenesis, we expect VEGF levels to 
be elevated following ischemia-induced hypoxia. Similarly, HIF1α is important in 
sensing low oxygen conditions. Since HIF1α is increased with hypoxia via positive 
feedback activation, it is expected that HIF1α mRNA be elevated after inducing the 
ischemic conditions.  
   
Specific Aim 1: To develop reliable molecular biology protocols that can be used 
to isolate nucleic acids and measure the gene expression levels of specific genes-
of-interest. The accuracy of this approach will be determined by measuring the 
expression of genes HIF1α and VEGF, which are known to increase following 
ischemia. We expect expression levels to be highest at day 7 following surgery, 
and decline slightly at day 14. 
 
Specific Aim 2:  To determine if the modified resection surgery will be viable in 
evaluating angiogenesis. The purpose of this aim is to validate phenotype 
observations with molecular analysis.  
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Chapter 3. Methods 
ANIMAL HUSBANDRY 
 All procedures for this study were reviewed and approved by the Institutional 
Animal Care and Use Committee (IACUC) of California Polytechnic State University. 
Male C57/Bl/6 mice, aged between 7-9 weeks, were housed in a temperature controlled 
room within the University Vivarium with four mice per micro-isolator cage. Mice were 
monitored on a daily basis, given water and rodent chow, and maintained a 12 hour light/ 
12 hour dark schedule. Mice were provided with nesting material, a mouse house, and a 
plastic tube. Isolation gowns were worn while changing cages to maintain aseptic 
conditions.  
 
CHRONIC ISCHEMIA SURGERY 
 Mice were anesthetized in an induction chamber using 5% isoflurane and oxygen. 
Once unconscious, the animal was removed from the chamber, weighed, and prepared for 
the surgery. Surgical preparation included shaving the incision site and then removing 
excess fur using depilatory cream. Finally, the mouse was placed onto a heated surgical 
stage in a supine position. Body temperature was monitored and maintained throughout 
the procedure at ~35⁰C via a rectal thermistor and heating pad.  
 The site of incision was wiped with Nolvasan to disinfect the area and a sterile 
drape was placed over the animal with an opening only over the surgical region. A skin 
incision was then made on the medial part of the hindlimb and elongated proximally until 
the abdominal wall was visible. Sterile saline solution was applied to the site of incision 
via a sterile cotton swab to help prevent the tissue from desiccating and becoming 
damaged.  
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 Once the incision site was fully opened and prepared, the epigastric fat pad was 
cauterized and removed. Next, the femoral artery was separated from the paired nerve 
and vein, and sutures were tied on either side of the profunda bifurcation as seen in 
figure 5. Following the ligation around the bifurcation, the segment of the vessel between 
the two sutures was resected. 
 
  
 
On the opposite hindlimb, an incision was made equivalent in size and location. 
Again, sterile saline was used to prevent tissue desiccation. The fat pad and connective 
tissue were blunt dissected as they were on the experimental leg. This sham surgery was 
performed on the animal’s right leg to serve as a control for the potential impact of the 
surgery on vascular remodeling.  
Saphenous artery & vein 
Profunda femoris vein 
Profunda femoris artery 
Gracilis muscles & collaterals  
Figure 5.  Mouse hind limb used to model the ischemic conditions caused 
by vascular occlusions. “X’s” on the femoral artery, on both the distal and 
proximal sides of the profunda bifurcation, represent suture locations. The 
dashed line represents the segment of femoral artery resected.  
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Incisions were closed using a 7.0 polypropylene suture and the mouse was given a 
subcutaneous injection of buprenorphine (0.07 mg/kg). Animals were then placed back in 
their appropriate cage and given 7 or 14 days to recover, depending on their assigned 
time before their tissue was dissected.  
 
TISSUE DISSECTION AND PRESERVATION 
The gastrocnemius muscle was exposed by dissecting superficial musculature. 
The gastrocnemius was then blunt dissected away from other muscle and separated away 
from the tibia and fibula. The muscle was dissected from the calcaneal tendon to its 
insertion at the condyles of the femur.  
 Immediately follow the dissection from the mouse, the tissue was placed in 1 
volume (~1 mL) of RNAlater Stabilization solution (Invitrogen) and stored overnight at 
4 C (Appendix A). After the overnight incubation the tissue was removed from solution 
and place in a fresh microcentrifuge tube. Once in a new tube, the samples were 
transferred to a -20 C freezer where they could be stored indefinitely.  
 
TISSUE PREPARATION, RNA ISOLATION, QUANTIFICATION, AND QUALIT Y 
ASSESSMENT 
Tissue was homogenized using a Wheaton Glass Homogenizer (figure 6). Total 
RNA was isolated using Qiagen fibrous tissue mini kit (Appendix B), which is ideal for 
muscle tissues weighing less than 30 mg. -mercaptoethanol was added to lysis buffer to 
aid in RNase denaturation. An on-column DNA digest was performed using Qiagen 
DNase I kit. Water was used to wash the salts and release the nucleic acids from the 
membrane. Following isolation, the RNA was quantified using UV spectrophotometry 
(Thermo Scientific Nanodrop 2000) (figure 7). In order to quantify, the 
spectrophotometer was zeroed with water and the absorbance was measured across the 
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spectrum from 200 to 300 nanometers (Appendix C). In order to check the integrity of the 
RNA isolated, a 1% agarose gel containing ethidium bromide was run at 125V for about 
45 minutes using 1X TAE running buffer. The gel was then imaged under UV light and 
the ribosomal bands were analyzed. Upon analysis of the RNA, high quality samples 
were carried on to the next part of the experiment. 
   
 
 REVERSE TRANSCRIPTION, PCR, AND REAL-TIME PCR 
RNA was converted into cDNA using the AffinityScript Multiple Temperature 
Reverse Trancriptase kit from Agilent Technologies with oligo-dT primers annealed at 
48 C. Using the concentration provided from the nanodrop spectrophotometer analysis, 
2000 ng of total RNA was added to each reverse transcription reaction. HIF1α, VEGF, 
and -actin primers were designed for real time PCR; table 1 shows the nucleotide 
sequences for the oligo-nucleotide primers designed from gene database information and 
messenger RNA sequences. -actin was used as the internal control gene to normalize the 
amount of RNA added to each PCR reaction. 
Primers were designed to bind to the messenger RNA transcripts of genes using 
the sequences provided from the NCBI database (Appendix D). The primers bind to very 
Figure 7. Thermo 
scientific Nanodrop 
2000 used to quantify 
nucleic acid 
concentration [28].  
Figure 6. Wheaton® 
Glass Homogenizer 
used to homogenize 
tissue [27]. 
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specific sequences of DNA, or in this case cDNA and provide the three prime alcohol 
group on the nucleic acid essential for polymerase to catalyze the phosphodiester bond 
formed while replicating the nucleic acid template.  BLAST was used to assure that the 
primers were specific and unique in the Mus musculus genome. 
Following the completion of cDNA synthesis, primers were optimized using 
gradient PCR with annealing temperatures from 54-62 C using Qiagen HotStar Taq DNA 
Polymerase in 25 L reaction volumes. Reactions were prepared according to Appendix 
E and the cycle conditions were performed using manufacturer recommendations. 
Qiagen QuantiFast SYBR Green (figure 8) PCR Kit was used for real time 
detection using an Applied Biosystems  7500 Fast Real-time PCR System. The real time 
protocol was 40 cycles of denaturing, annealing, and extending phases. An annealing 
temperature of 58 C was used for all primer sets. After the final cycle, a dissociation 
stage was used to ensure that there was no contamination within the sample. Samples 
were analyzed in triplicate reactions and the CT values were averaged together. Also, 
non-template controls were run with each primer set. 
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Figure 8. Diagram of SYBR green detector functions 
during the PCR to determine the amount of transcript 
present. Fluorescence is detected by Applied 
Biosystems thermocycler [29]. 
Primer Sequence Primer Size Amplicon Size 
HIF 1a forward 5’-agttacagaaacctaccatcactgc-3’ 25 136 
HIF 1a reverse 5’-tcttgaggtacttgggtagaagatg-3’ 25  
VEGF forward 5’-ctctctcttatttgacttgtgtgtgtg-3’ 28 133 
VEGF reverse 5’-aatatcttctcaggacaagctagtgac-3’ 27  
-actin forward 5’-ctgacagactacctcatgaagatcc-3’ 25 114 
-actin reverse 5’-gtctagagcaacatagcacagcttc-3’ 25  
 
 
 
 
  
 
 
 
 
Table 1. Primers used during real time PCR gene expression analysis. Including sequences, 
primer size, and expected amplicon size. 
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DATA ANALYSIS USING THE  METHOD 
 Using the  method [30], the data collected was measured as the fold change 
in gene expression after normalization to the reference gene. A comparison was then 
made between control and treatment groups. For the treatment group, evaluation of the 
 value indicates the fold change in gene expression relative to the untreated control 
group. A one way T-test was used for statistical comparison between groups. A p-value 
less that 0.05 was considered statistically significant.  
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Chapter 4. Results 
RNAlater® Stabilization solution provided an effective and reliable method of 
preservation following dissection from the mice. Figure 9 shows total RNA isolated from 
gastrocnemius muscles. Overall RNA quality was assessed by observing the ribosomal 
RNA bands in the agarose gel image. The bands seen in samples (lanes 2-8 of figure 9) 
are the 28s and 18s bands that make up eukaryotic ribosomes. The top band in each lane, 
28s is roughly twice as bright as the 18s band, as expected in the absence of RNA 
degradation. Therefore, it is assumed that messenger RNA was not significantly degraded 
during the isolation process. As an additional check for RNA quality, there were no signs 
of small segments of degraded RNA, which present as a “smear” towards the bottom of 
the gel image. An example of this is shown in Appendix F. Similarly, there was no 
evidence of genomic DNA contamination in the sample, which would have presented as a 
large band towards the top of the gel image. The smears observed in figure 9 represent 
messenger RNA.  
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Figure 9. Gel electrophoresis visualization of total RNA isolated from gastrocnemius 
samples. Total RNA was separated using a 1% non-denaturing agarose gel containing 
ethidium bromide and photographed under ultraviolet light. The gel was run at 125V 
for 45 minutes. The two bands in each sample represent the ribosomal RNA bands. 
Lane 1 contains Promega 1kb standard ladder. 
 1 2 3 4 5 6 7 8 
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Once quality RNA was reverse transcribed into cDNA, PCR primers were 
optimized to ensure proper annealing temperatures for the real-time PCR. The highest 
quality amplicon was generated when primers were annealed at 58°C, as observed in 
figure 10. The high quality was assessed by looking for the brightest and sharpest band 
of the amplicons. These characteristics combined represent consistent and accurate 
binding of the primers, while not making the temperature too high to where the primers 
are unable to bind. The same annealing temperature was used for all sets of primers 
during the real-time PCR experiments following primer optimization.  
 
 
Figure 10. Gel electrophoresis visualization of gradient PCR 
amplicons. The bands were separated using a 2% non-
denaturing agarose gel containing ethidium bromide and 
photographed under ultraviolet light.  Gel was run at 125V for 
45 minutes. PCR gradient was used to determine the optimal 
annealing temperature for primers. In this case, VEGF 
amplicons were analyzed and 58 C happened to generate the 
highest quality band.
 
 
°C: 54 55 56 57 58 59 60 61 
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Using one set of primers per reaction, all samples were analyzed in one reaction, 
in a single 96-well tray. The results of one reaction are displayed in figure 11. The image 
shows little observable fluorescence during the early stages. However, after about 20 or 
so cycles, exponential amplification is observed, as expected. The fluorescence begins to 
plateau towards the latter cycles as the primers become limiting reactants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 11. Real time PCR amplification plot of gastrocnemius muscle samples using 
HIF1a primers. Primers were annealed at 58 C. An extension time of 30 seconds was 
used.  
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In order to extract the CT value from the reaction data, the graph was converted 
into change per reaction vs cycle number, as shown in figure 12. The threshold value was 
chosen at a value where the amplification curve was steepest in all samples. A 
dissociation-curve analysis was also performed to determine the melting temperature of a 
single target nucleic acid sequence. Therefore, if there were any contamination within the 
sample, an errant curve would be generated.  
 
 
The CT values for HIF-1α and VEGF can be found in tables 2-5. From these 
values, the bar graphs were generated for visual comparison of the data (figures 13 and 
Figure 12. Real time PCR amplification plot of gastrocnemius muscle samples using 
HIF1a primers. The horizontal line represents the threshold used to analyze the samples.  
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14). The analysis reveals no significant changes in HIF1α expression following the 
surgery. Conversely, there was a significant increase in VEGF expression at both 7 and 
14 days. VEGF expression levels dropped significantly between the day 7 and day 14 
time points in experimental tissue as well.  
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 Table 2. Replicate day 7 CT data comparison of HIF1α and β-actin reference amplified in separate wells. 
Data generated using real-time PCR with SYBR green detector. 
Tissue  HIF1α β-actin ΔCT (Avg. HIF1α 
CT – Avg. β-actin 
CT) 
ΔΔCT (Avg. ΔCT,Sham 
– Avg. ΔCT) 
Normalized HIF1α 
amount relative to Sham 
 
Sham 20.99 
21.40 
21.48 
15.88 
16.14 
16.32 
   
Average 21.29 ± 0.15 16.11 ± 0.13 5.18 ± 0.04 0.00 ± 0.04 1.00(0.97-1.03) 
Day 7 21.18 
20.23 
18.62 
15.89 
15.18 
13.55 
   
Average 20.01 ± 0.75 14.88 ± 0.69 5.13 ± 0.07 0.05 ± 0.07 0.97(0.92-1.01) 
 
 
Table 3. Replicate day 14 CT data comparison of HIF1α and β-actin reference amplified in separate 
wells. Data generated using real-time PCR with SYBR green detector. 
Tissue  HIF1α β-actin ΔCT (Avg. HIF1α 
CT – Avg. β-actin 
CT) 
ΔΔCT (Avg. ΔCT,Sham 
– Avg. ΔCT) 
Normalized HIF1α 
amount relative to Sham 
 
Sham 21.40 
22.18 
21.63 
21.05 
15.94 
16.57 
16.41 
15.73 
   
Average 21.57 ± 0.24 16.16 ± 0.20 5.41 ± 0.09 0.00 ± 0.09 1.00(0.94-1.06) 
Day 14 23.47 
21.09 
21.02 
20.89 
17.06 
15.30 
15.69 
15.85 
   
Average 21.62 ± 0.62 15.97 ± 0.38 5.65 ± 0.30 -0.24 ± 0.30 1.18(0.96-1.45) 
 
 
Figure 13. Delta CT analysis of HIF1α compared against β-actin in gastrocnemius muscle. Results 
measured at days 7 and 14 in both experimental and sham tissue. The error bars represent the standard 
error of the mean.  
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Table 4. Replicate day 7 CT data comparison of VEGF and β-actin reference amplified in separate 
wells. Data generated using real-time PCR with SYBR green detector. 
Tissue VEGF β-actin ΔCT (Avg. VEGF CT 
– Avg. β-actin CT) 
ΔΔCT (Avg. ΔCT,Sham 
–Avg. ΔCT ) 
Normalized VEGF 
amount relative to Sham 
 
Sham 17.64 
17.74 
17.19 
15.88 
16.14 
16.32 
   
Average 17.52 ± 0.17 16.11 ± 0.13 1.41 ± 0.27 0.00 ± 0.27 1.00(0.83-1.21) 
Day 7 18.29 
18.04 
19.58 
15.89 
15.18 
13.55 
   
Average 18.64 ± 0.48 14.88 ± 0.69 3.76 ± 1.14 -2.35 ± 1.14 5.10(2.31-11.24) 
 
 
Table 5. Replicate day 14 CT data comparison of VEGF and β-actin reference amplified in separate 
wells. Data generated using real-time PCR with SYBR green detector. 
Tissue  VEGF β-actin ΔCT (Avg. VEGF 
CT – Avg. β-actin 
CT) 
ΔΔCT (Avg. ΔCT,Sham 
– Avg. ΔCT) 
Normalized VEGF 
amount relative to Sham 
 
Sham 17.47 
18.49 
17.48 
16.80 
15.94 
16.57 
16.41 
15.73 
   
Average 17.56 ± 0.35 16.16 ± 0.20 1.40 ± 0.21 0.00 ± 0.21 1.00(0.86-1.16) 
Day 14 18.69 
17.53 
18.27 
17.12 
17.06 
15.30 
15.69 
15.85 
   
Average 17.90 ± 0.35 15.97 ± 0.38 1.93 ± 0.29 -0.53 ± 0.29 1.44(1.18-1.77) 
 
 
 
Figure 14. Delta CT analysis of VEGF compared against β-actin in gastrocnemius muscle. Results 
measured at days 7 and 14 in both experimental and sham tissue. The error bars represent the standard 
error of the mean. 
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Chapter 5. Discussion 
 PAD is a vascular condition characterized by the narrowing of blood vessels 
caused by the buildup of atherosclerotic plaques and the reduced reactivity of 
downstream vessels. Together, these factors result in ischemia and cause damage to the 
effected tissue. As an adaptive mechanism, blood is redistributed amongst collateral 
vessels, which in turn results in increased shear stress within those vessels and causes 
them to outwardly remodel. However, outward remodeling itself may impair vasodilation 
and lead to ischemic limb pain in patients. Impaired vasodilation might be caused by 
changes in cell type during the angiogenesis process, specifically the transition of smooth 
muscle cells from contractile to synthetic. It may also be caused from the relocation of 
cells during mechanoadaptation. A third possibility for the observed impairment in 
vasodilation could be a decrease in endothelial-derived nitric oxide as a result of 
inflammation brought on by the increased shear stress. Inducing vascular remodeling in 
patients with vascular occlusions is a promising new route in the treatment of PAD. 
However, to create an effective therapy, the impact of vascular growth on vasoactivity 
must first be better understood.  
 The first objective of this project was to develop reliable molecular biology 
protocols that could be used to evaluate vascular remodeling and vasoactivity. As 
evidenced by figures 9, 10, 11 & 12, the protocols developed successfully yielded 
consistent, high-quality nucleic acid isolations and precise real-time PCR reactions. 
Several different aspects of molecular biology were addressed and developed during this 
project, and a great deal of optimization was required for the PCR protocol.  
Primers for PCR were selected if they met several prerequisites. First, the 
amplicon generated had to be short, less than 150 base pairs. This is a requirement of 
30 
 
primers that will later be used during real-time PCR because it allows for polymerase to 
bind, amplify, and unbind quickly. Second, primers had to be slightly longer than lose 
used during regular PCR to ensure nonspecific binding did not occur. In this case, each 
primer was at least 25 base pairs in length. Third, the melting temperatures between each 
primer of the pair had to be highly similar to each other to allow for efficient annealing. 
Finally, the final base pair at the three prime end had to be either a guanine or cytosine. 
 The second objective of this project was to determine if the modified resection 
surgery was a viable method in evaluating angiogenesis. The results for this are shown in 
figures 13 & 14. The increase in Vegf expression in the day 7 measurement following 
surgery indicates that the surgery sufficiently created a hypoxic environment in the 
downstream tissue. Vegf was most elevated when measured 7 days after the surgery. The 
decrease in Vegf expression from day 7 to day 14, suggests that the signals for 
vasculogenesis and angiogenesis were present and that these phenomenon may have been 
acting to remodel the vascular network and improve tissue oxygen extraction. The 
significant decrease in Vegf transcript levels between days 7 and 14 following the 
surgery, suggests that vascular remodeling caused a decrease in tissue hypoxia. The 
value, however, was still higher than the sham, which implies that after 14 days the tissue 
remains slightly hypoxic and continued vascular remodeling was still necessary.  
Surprisingly, there were no significant changes in Hif1α expression between the 
sham and experimental tissues at either 7 or 14 days (figure 13). These results suggest 
that the modified ischemic model induces a less severe hypoxia than the traditional 
ischemia model that involves resection of the entire femoral-saphenous artery-vein pair. 
From the Vegf increase it is apparent that the tissue became hypoxic, however, the Hif1α 
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results suggest that the hypoxia was not enough to generate the positive feedback of 
Hif1α necessary for the increase in its transcription [31]. These assumptions can be easily 
verified using protein quantification, such as a western blot analysis. Results from a 
western blot would be able to detect the amount of Hif1α present and help confirm that 
more active amounts of protein are present even though there was no significant increase 
in transcript level.  
 The results from this project do not provide conclusions regarding the relationship 
between vascular remodeling and vasoactivity, but rather provides the necessary 
techniques required to investigate this topic. For example, measurement of Embyronic 
smooth muscle myosin (SMemb) would provide an independent measure of 
arteriogenesis. This would provide valuable information on the remodeling process and 
the impaired vasodilation observed during arteriogenesis that is thought to be caused by 
the phenotype changes the vascular smooth muscle cells.  
 Another application of the protocols and procedures developed in this project is 
the analysis of gene delivery techniques. Plasmids are being developed that would allow 
genes, such as Vegf, to be delivered directly into the tissues of experimental animals, 
which would allow for both gain- and loss-of-function studies at the genetic level. Using 
the real-time protocols developed for this project, the efficiency of transgene expression 
could be easily measured.  
 Overall, the protocols developed in during this project allowed for an accurate and 
concise analysis of the genes investigated. The modified resection surgery was sufficient 
in creating a hypoxic environment downstream to the point where the genes involved in 
vascular remodeling were significantly up-regulated. Upcoming studies using this model 
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should incorporate protein analysis to gain a more complete picture of the environment at 
the molecular level. Better understanding the interactions between vasodilation and 
vascular remodeling can guide the development of novel treatments for patients afflicted 
with PAD.  
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APPENDIX A 
TISSUE DISECTION PROTOCOL 
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APPENDIX B 
RNA ISOLATION PROTOCOL  
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APPENDIX C 
RNA ANALYSIS PROTOCOL 
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APPENDIX D 
ADDITIONAL INFORMATION REGARDING PRIMER DESIGN 
The final base pair at the three prime end had to be either a guanine or cytosine. 
These nucleic acids, when bonded with each other in a double stranded manner, are held 
together by three hydrogen bonds, rather than the two that hold together adenine and 
thymine base pairs. This extra hydrogen bond helps ensure that the three prime end of the 
primer is firmly attached to its template before amplification begins. 
 
APPENDIX E 
MODIFIED PCR AMPLIFICATION PROTOCOL 
The concentration of reagents was modified from manufacturer protocol to a more 
efficient reaction that was found to produce better results. 
 
 
  
Date__________ PCR Master Mix Protocol Initials__________ 
MASTER MIX REAGENTS INITIAL CONC FINAL CONC 1 RXN (µL) 
ADDED TO MM    
PCR Buffer 10X 1X 2.5 
Q Solution 5X 1X 5 
Hot Star Taq Pols 5U / µL 2.5U / rxn 0.5 
MgCl2 25 mM 2.5 mM 2.5 
dNTPs 10 mM 0.20 mM 0.5 
Di H2O   9 
    
  VOLUME / ALIQUOT (µL) 20 
ADDED AFTER MM ALIQUOTED    
Primer  10 µM 1 µM 2.5 
Amount sample  100 ng/µL 250 ng 2.5 
  TOTAL RXN VOL (µL) 25 
 
Notes: 
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APPENDIX F 
 The image below is an example of an isolation of heavily degraded RNA. The 
bright band towards the bottom of the gel image in lane 4 is an example of heavily 
degraded RNA. RNA this heavily degraded cannot be used for later experiments such as 
real-time PCR for gene expression analysis because the results will be inaccurate.  
  
 1 2 3 4 5 6 
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APPENDIX G 
REAL-TIME PCR DATA FOR HIF1Α 
The fluorescence begins to plateau towards the latter cycles as the primers 
become limiting reactants. By that point in the reaction, the concentration of primers is 
not high enough in solution to maintain the trend and amplification ceased. Also, with 
each primer set, a non-template control sample was used to confirm that SYBR green 
detection was in fact from the amplification of transcripts. 
 
Document Name: AT primer 7 C11-D12 
Plate Type: Standard Curve
User: CAFES USER
Document Information
Operator: CAFES USER
Run Date: Monday March 19  2012 21:24:00
Last Modified: Tuesday March 20  2012 11:37:31
Instrument Type: Applied Biosystems 7500 Fast Real-Time PCR System
Exporting Mode: Based on Selected Wells and Report Setting
Comments:
SDS v1.4
Thermal Cycler Profile
Stage Repetitions Temperature Time Ramp Rate Auto Increment
1 1 95.0 ! C 15:00 Auto
2 40 94.0 ! C 0:15 Auto
58.0 ! C 0:30 Auto
72.0 ! C 0:30 Auto
3 (Dissociation) 1 95.0 ! C 0:15 Auto
60.0 ! C 1:00 Auto
95.0 ! C 0:15 Auto
60.0 ! C 0:15 Auto
Fast 7500 Mode
Data Collection :  Stage 2 Step 3
PCR Volume: 20 " L
Well Sample Name Detector Task Ct StdDev Ct Tm
A1 C11 Primer 7 SYBR Unknown 21.2963 0.136-999.9 77.2
A2 C11 Primer 7 SYBR Unknown 21.3609 0.136-999.9 77.2
A3 C11 Primer 7 SYBR Unknown 21.5574 0.136-999.9 77.2
A4 C12 Primer 7 SYBR Unknown 23.3481 0.106-999.9 77.2
A5 C12 Primer 7 SYBR Unknown 23.5331 0.106-999.9 77.2
A6 C12 Primer 7 SYBR Unknown 23.5301 0.106-999.9 77.5
A7 D1 Primer 7 SYBR Unknown 22.2525 0.102-999.9 77.5
A8 D1 Primer 7 SYBR Unknown 22.2278 0.102-999.9 77.2
A9 D1 Primer 7 SYBR Unknown 22.0649 0.102-999.9 77.2
A10 D2 Primer 7 SYBR Unknown 21.0123 0.0876-999.9 77.2
A11 D2 Primer 7 SYBR Unknown 21.1868 0.0876-999.9 77.2
A12 D2 Primer 7 SYBR Unknown 21.0855 0.0876-999.9 77.2
B1 D3 Primer 7 SYBR Unknown 21.5033 0.111-999.9 77.2
B2 D3 Primer 7 SYBR Unknown 21.7075 0.111-999.9 77.5
B3 D3 Primer 7 SYBR Unknown 21.6828 0.111-999.9 77.5
B4 D4 Primer 7 SYBR Unknown 20.9387 0.0914-999.9 77.5
B5 D4 Primer 7 SYBR Unknown 21.0102 0.0914-999.9 77.5
B6 D4 Primer 7 SYBR Unknown 21.1202 0.0914-999.9 77.5
B7 D5 Primer 7 SYBR Unknown 21.1821 0.117-999.9 77.5
B8 D5 Primer 7 SYBR Unknown 20.9872 0.117-999.9 77.5
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B9 D5 Primer 7 SYBR Unknown 20.9741 0.117-999.9 77.5
B10 D6 Primer 7 SYBR Unknown 20.8359 0.163-999.9 77.5
B11 D6 Primer 7 SYBR Unknown 21.0668 0.163-999.9 77.5
B12 D6 Primer 7 SYBR Unknown 20.7528 0.163-999.9 77.5
C1 D7 Primer 7 SYBR Unknown 20.7743 0.216-999.9 77.5
C2 D7 Primer 7 SYBR Unknown 20.991 0.216-999.9 77.9
C3 D7 Primer 7 SYBR Unknown 21.2071 0.216-999.9 77.9
C4 D8 Primer 7 SYBR Unknown 21.1458 0.0276-999.9 77.9
C5 D8 Primer 7 SYBR Unknown 21.1805 0.0276-999.9 77.9
C6 D8 Primer 7 SYBR Unknown 21.2003 0.0276-999.9 77.9
C7 D9 Primer 7 SYBR Unknown 21.3617 0.0472-999.9 77.9
C8 D9 Primer 7 SYBR Unknown 21.4545 0.0472-999.9 77.9
C9 D9 Primer 7 SYBR Unknown 21.3927 0.0472-999.9 77.9
C10 D10 Primer 7 SYBR Unknown 20.2274 0.146-999.9 77.9
C11 D10 Primer 7 SYBR Unknown 20.3836 0.146-999.9 77.9
C12 D10 Primer 7 SYBR Unknown 20.0916 0.146-999.9 77.5
D1 D11 Primer 7 SYBR Unknown 21.5241 0.135-999.9 77.5
D2 D11 Primer 7 SYBR Unknown 21.3261 0.135-999.9 77.9
D3 D11 Primer 7 SYBR Unknown 21.5831 0.135-999.9 77.9
D4 D12 Primer 7 SYBR Unknown 18.7977 0.253-999.9 78.2
D5 D12 Primer 7 SYBR Unknown 18.7229 0.253-999.9 78.2
D6 D12 Primer 7 SYBR Unknown 18.3267 0.253-999.9 78.2
D7 NTC Primer 7 SYBR NTC 38.0194 -999.9 77.5
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APPENDIX H 
REAL-TIME PCR DATA FOR VEGF 
 
  
Document Name: Primer 10 C11-D12 
Plate Type: Standard Curve
User: CAFES USER
Document Information
Operator: CAFES USER
Run Date: Tuesday March 20  2012 13:03:50
Last Modified: 
Instrument Type: Applied Biosystems 7500 Fast Real-Time PCR System
Exporting Mode: Based on Selected Wells and Report Setting
Comments:
SDS v1.4
Thermal Cycler Profile
Stage Repetitions Temperature Time Ramp Rate Auto Increment
1 1 95.0 ! C 15:00 Auto
2 40 94.0 ! C 0:15 Auto
58.0 ! C 0:30 Auto
72.0 ! C 0:30 Auto
3 (Dissociation) 1 95.0 ! C 0:15 Auto
60.0 ! C 1:00 Auto
95.0 ! C 0:15 Auto
60.0 ! C 0:15 Auto
Fast 7500 Mode
Data Collection :  Stage 2 Step 3
PCR Volume: 20 " L
Well Sample Name Detector Task Ct StdDev Ct Tm
A1 C11 Primer 10SYBR Unknown 17.4152 0.0847-999.9 78
A2 C11 Primer 10SYBR Unknown 17.4305 0.0847-999.9 78
A3 C11 Primer 10SYBR Unknown 17.569 0.0847-999.9 78
A4 C12 Primer 10SYBR Unknown 18.6176 0.0596-999.9 78
A5 C12 Primer 10SYBR Unknown 18.7087 0.0596-999.9 78.4
A6 C12 Primer 10SYBR Unknown 18.7297 0.0596-999.9 78.4
A7 D1 Primer 10 SYBR Unknown 18.6099 0.148-999.9 78.4
A8 D1 Primer 10 SYBR Unknown 18.5293 0.148-999.9 78.4
A9 D1 Primer 10 SYBR Unknown 18.3223 0.148-999.9 78
A10 D2 Primer 10 SYBR Unknown 17.8149 0.485-999.9 78
A11 D2 Primer 10 SYBR Unknown 17.7977 0.485-999.9 78
A12 D2 Primer 10 SYBR Unknown 16.966 0.485-999.9 78
B1 D3 Primer 10 SYBR Unknown 17.4624 0.0217-999.9 78
B2 D3 Primer 10 SYBR Unknown 17.5023 0.0217-999.9 78.4
B3 D3 Primer 10 SYBR Unknown 17.4675 0.0217-999.9 78.4
B4 D4 Primer 10 SYBR Unknown 18.2137 0.0564-999.9 78.4
B5 D4 Primer 10 SYBR Unknown 18.2735 0.0564-999.9 78.4
B6 D4 Primer 10 SYBR Unknown 18.3265 0.0564-999.9 78.4
B7 D5 Primer 10 SYBR Unknown 16.9941 0.171-999.9 78.4
B8 D5 Primer 10 SYBR Unknown 16.7111 0.171-999.9 78.4
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B9 D5 Primer 10 SYBR Unknown 16.6862 0.171-999.9 78.4
B10 D6 Primer 10 SYBR Unknown 17.0526 0.0908-999.9 78.4
B11 D6 Primer 10 SYBR Unknown 17.2266 0.0908-999.9 78.4
B12 D6 Primer 10 SYBR Unknown 17.0948 0.0908-999.9 78.4
C1 D7 Primer 10 SYBR Unknown 17.5036 0.184-999.9 78.4
C2 D7 Primer 10 SYBR Unknown 17.5661 0.184-999.9 78.7
C3 D7 Primer 10 SYBR Unknown 17.8482 0.184-999.9 78.7
C4 D8 Primer 10 SYBR Unknown 18.1287 0.166-999.9 78.7
C5 D8 Primer 10 SYBR Unknown 18.4606 0.166-999.9 78.7
C6 D8 Primer 10 SYBR Unknown 18.2781 0.166-999.9 78.7
C7 D9 Primer 10 SYBR Unknown 17.7045 0.0437-999.9 78.7
C8 D9 Primer 10 SYBR Unknown 17.7911 0.0437-999.9 78.7
C9 D9 Primer 10 SYBR Unknown 17.7376 0.0437-999.9 78.7
C10 D10 Primer 10SYBR Unknown 18.0978 0.251-999.9 78.7
C11 D10 Primer 10SYBR Unknown 18.253 0.251-999.9 78.7
C12 D10 Primer 10SYBR Unknown 17.7626 0.251-999.9 78.4
D1 D11 Primer 10SYBR Unknown 17.2861 0.123-999.9 78.7
D2 D11 Primer 10SYBR Unknown 17.0507 0.123-999.9 78.7
D3 D11 Primer 10SYBR Unknown 17.2288 0.123-999.9 79.1
D4 D12 Primer 10SYBR Unknown 19.5339 0.0517-999.9 79.1
D5 D12 Primer 10SYBR Unknown 19.6372 0.0517-999.9 78.7
D6 D12 Primer 10SYBR Unknown 19.5838 0.0517-999.9 78.7
D7 Primer 10 NTCSYBR NTC 37.7438 -999.9 78
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APPENDIX I 
REAL-TIME PCR DATA FOR β-ACTIN 
 
  
Document Name: AT primer 13 C11-D12 
Plate Type: Standard Curve
User: CAFES USER
Document Information
Operator: CAFES USER
Run Date: Wednesday March 21  2012 11:25:52
Last Modified: Wednesday March 21  2012 13:17:13
Instrument Type: Applied Biosystems 7500 Fast Real-Time PCR System
Exporting Mode: Based on Selected Wells and Report Setting
Comments:
SDS v1.4
Thermal Cycler Profile
Stage Repetitions Temperature Time Ramp Rate Auto Increment
1 1 95.0 ! C 15:00 Auto
2 40 94.0 ! C 0:15 Auto
58.0 ! C 0:30 Auto
72.0 ! C 0:30 Auto
3 (Dissociation) 1 95.0 ! C 0:15 Auto
60.0 ! C 1:00 Auto
95.0 ! C 0:15 Auto
60.0 ! C 0:15 Auto
Fast 7500 Mode
Data Collection :  Stage 2 Step 3
PCR Volume: 20 " L
Well Sample Name Detector Task Ct StdDev Ct Tm
A1 C11 Primer 13SYBR Unknown 15.8949 0.0758-999.9 80.4
A2 C11 Primer 13SYBR Unknown 15.8978 0.0758-999.9 80.4
A3 C11 Primer 13SYBR Unknown 16.0277 0.0758-999.9 80.4
A4 C12 Primer 13SYBR Unknown 16.9606 0.0858-999.9 80.4
A5 C12 Primer 13SYBR Unknown 17.1263 0.0858-999.9 80.7
A6 C12 Primer 13SYBR Unknown 17.0818 0.0858-999.9 80.7
A7 D1 Primer 13 SYBR Unknown 16.7705 0.2-999.9 80.7
A8 D1 Primer 13 SYBR Unknown 16.5714 0.2-999.9 80.7
A9 D1 Primer 13 SYBR Unknown 16.3706 0.2-999.9 80.4
A10 D2 Primer 13 SYBR Unknown 15.3161 0.136-999.9 80.4
A11 D2 Primer 13 SYBR Unknown 15.4255 0.136-999.9 80.4
A12 D2 Primer 13 SYBR Unknown 15.1555 0.136-999.9 80.4
B1 D3 Primer 13 SYBR Unknown 16.3013 0.168-999.9 80.4
B2 D3 Primer 13 SYBR Unknown 16.608 0.168-999.9 80.4
B3 D3 Primer 13 SYBR Unknown 16.3346 0.168-999.9 80.7
B4 D4 Primer 13 SYBR Unknown 15.5399 0.134-999.9 80.7
B5 D4 Primer 13 SYBR Unknown 15.7172 0.134-999.9 80.7
B6 D4 Primer 13 SYBR Unknown 15.8021 0.134-999.9 80.7
B7 D5 Primer 13 SYBR Unknown 15.9946 0.248-999.9 80.7
B8 D5 Primer 13 SYBR Unknown 15.6791 0.248-999.9 80.7
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B9 D5 Primer 13 SYBR Unknown 15.5064 0.248-999.9 80.4
B10 D6 Primer 13 SYBR Unknown 15.8725 0.0229-999.9 80.7
B11 D6 Primer 13 SYBR Unknown 15.8529 0.0229-999.9 80.7
B12 D6 Primer 13 SYBR Unknown 15.8269 0.0229-999.9 80.4
C1 D7 Primer 13 SYBR Unknown 15.6862 0.184-999.9 80.4
C2 D7 Primer 13 SYBR Unknown 15.8885 0.184-999.9 80.7
C3 D7 Primer 13 SYBR Unknown 16.0529 0.184-999.9 80.7
C4 D8 Primer 13 SYBR Unknown 15.7228 0.149-999.9 81.1
C5 D8 Primer 13 SYBR Unknown 15.9854 0.149-999.9 81.1
C6 D8 Primer 13 SYBR Unknown 15.9761 0.149-999.9 81.1
C7 D9 Primer 13 SYBR Unknown 16.162 0.103-999.9 80.7
C8 D9 Primer 13 SYBR Unknown 16.2303 0.103-999.9 80.7
C9 D9 Primer 13 SYBR Unknown 16.0277 0.103-999.9 80.7
C10 D10 Primer 13SYBR Unknown 15.2259 0.123-999.9 81.1
C11 D10 Primer 13SYBR Unknown 15.2715 0.123-999.9 80.7
C12 D10 Primer 13SYBR Unknown 15.0399 0.123-999.9 80.7
D1 D11 Primer 13SYBR Unknown 16.4124 0.12-999.9 80.7
D2 D11 Primer 13SYBR Unknown 16.1816 0.12-999.9 81.1
D3 D11 Primer 13SYBR Unknown 16.3556 0.12-999.9 81.1
D4 D12 Primer 13SYBR Unknown 13.4667 0.09-999.9 81.4
D5 D12 Primer 13SYBR Unknown 13.5432 0.09-999.9 81.4
D6 D12 Primer 13SYBR Unknown 13.6461 0.09-999.9 81.1
D7 Primer 13 NTCSYBR NTC Undetermined 65.7
